Join our daily newsletter At The Bell to receive exclusive market insights
- Medgate has begun a three-month pilot trial of ResApp Health’s (RAP) smartphone-based acute respiratory diagnostic test across its telemedicine services in Switzerland
- ResAppDx is a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency departments and primary care settings
- Both ResApp and Medgate will assess the impact of ResAppDx on Medgate’s telehealth service through a number of key performance indicators
- The companies will enter into broader negotiations should the outcome of the trial be successful
- ResApp is in the grey, last trading at 5.9 cents
Medgate’s three-month pilot trial of ResApp Health’s (RAP) smartphone-based acute respiratory diagnostic test has begun across its telemedicine services in Switzerland.
Medgate is a provider of telehealth services, operating the largest telemedical centre run by doctors in Europe since 2000.
During the integration process, ResApp and Medgate worked collaboratively to conduct clinical and technical reviews of the technology, known as ResAppDx.
ResAppDx is a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency departments and primary care settings.
“We are absolutely convinced that the use of new technologies like ResAppDx will enable an advancement of our digital health platform. This will benefit our patients by enabling them to be treated conclusively by phone or video in even more cases,” said Medgate CEO Dr Andy Fischer.
Testing of the technology included detailed mapping of user journeys for patients with respiratory disease symptoms, usability testing, the introduction of automated processes to enhance the patient experience, and the development of comprehensive training resources for clinical onboarding the maximise clinician confidence.
During the pilot, both ResApp and Medgate will assess the impact of ResAppDx on Medgate’s telehealth service through a number of key performance indicators.
“We are very confident that ResAppDx will provide considerable benefits for Medgate patients, physicians and insurers. Medgate has made a strong commitment to ResApp and both parties remain confident of a successful pilot trial,” said CEO and Managing Director Dr Tony Keating.
“The company has already significantly benefitted from Medgate’s knowledge and insights into telehealth best practice, and we look forward to continuing this work into the future”.
The companies will enter into broader negotiations should the outcome of the trial be successful.
ResApp is in the grey, last trading at 5.9 cents at 11:00 am AEDT.
